162 related articles for article (PubMed ID: 7915152)
1. Pharmacology and toxicology of Cremophor EL diluent.
Dorr RT
Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
[No Abstract] [Full Text] [Related]
2. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
[No Abstract] [Full Text] [Related]
3. Case report--suspected anaphylactic reaction to Cremophor El.
Strachan EB
SAAD Dig; 1981 Jan; 4(9):209. PubMed ID: 6940248
[No Abstract] [Full Text] [Related]
4. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
5. Role of formulation vehicles in taxane pharmacology.
van Zuylen L; Verweij J; Sparreboom A
Invest New Drugs; 2001 May; 19(2):125-41. PubMed ID: 11392447
[TBL] [Abstract][Full Text] [Related]
6. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
7. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
8. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
[TBL] [Abstract][Full Text] [Related]
9. Alternative formulations of paclitaxel.
Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
[TBL] [Abstract][Full Text] [Related]
12. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
13. Is Cremophor EL, solvent for paclitaxel, cytotoxic?
Fjällskog ML; Frii L; Bergh J
Lancet; 1993 Oct; 342(8875):873. PubMed ID: 8104306
[No Abstract] [Full Text] [Related]
14. Cremophor EL, solvent for paclitaxel, and toxicity.
Liebmann J; Cook JA; Mitchell JB
Lancet; 1993 Dec; 342(8884):1428. PubMed ID: 7901713
[No Abstract] [Full Text] [Related]
15. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
[TBL] [Abstract][Full Text] [Related]
17. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
Gelderblom H; Verweij J; Nooter K; Sparreboom A
Eur J Cancer; 2001 Sep; 37(13):1590-8. PubMed ID: 11527683
[TBL] [Abstract][Full Text] [Related]
18. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Cancer; 1997 Mar; 79(6):1225-33. PubMed ID: 9070502
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
Li Y; Chen N; Palmisano M; Zhou S
Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
[TBL] [Abstract][Full Text] [Related]
20. Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
D'Errico S; Baldari B; Arcangeli M; Santurro A; Frati P; Fineschi V
Medicine (Baltimore); 2020 Oct; 99(43):e22814. PubMed ID: 33120804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
